MA37891B1 - Alcoxypyrazoles comme activateurs de guanylate cyclase soluble - Google Patents
Alcoxypyrazoles comme activateurs de guanylate cyclase solubleInfo
- Publication number
- MA37891B1 MA37891B1 MA37891A MA37891A MA37891B1 MA 37891 B1 MA37891 B1 MA 37891B1 MA 37891 A MA37891 A MA 37891A MA 37891 A MA37891 A MA 37891A MA 37891 B1 MA37891 B1 MA 37891B1
- Authority
- MA
- Morocco
- Prior art keywords
- alcoxypyrazoles
- activators
- compounds
- guanylate cyclase
- soluble guanylate
- Prior art date
Links
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 title 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
La présente invention concerne des composés de formule (i) : et ses sels pharmaceutiquement acceptables, r1, r2, r3, r4, r5, r6 et r7 étant tels que définis dans la description. L'invention concerne également des compositions pharmaceutiques comprenant ces composés, des procédés d'utilisation de ces composés dans le traitement de diverses maladies et affections et des procédés de préparation de ces composés et des intermédiaires utiles dans ces procédés.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261697899P | 2012-09-07 | 2012-09-07 | |
| PCT/US2013/057826 WO2014039434A1 (fr) | 2012-09-07 | 2013-09-03 | Alcoxypyrazoles comme activateurs de guanylate cyclase soluble |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37891A1 MA37891A1 (fr) | 2018-01-31 |
| MA37891B1 true MA37891B1 (fr) | 2018-05-31 |
Family
ID=49170904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37891A MA37891B1 (fr) | 2012-09-07 | 2013-09-03 | Alcoxypyrazoles comme activateurs de guanylate cyclase soluble |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US8906904B2 (fr) |
| EP (1) | EP2892891B1 (fr) |
| JP (1) | JP5970134B2 (fr) |
| KR (1) | KR101692707B1 (fr) |
| CN (1) | CN104619695B (fr) |
| AP (1) | AP2015008231A0 (fr) |
| AR (1) | AR092869A1 (fr) |
| AU (1) | AU2013312931B2 (fr) |
| BR (1) | BR112015004529B1 (fr) |
| CA (1) | CA2880494C (fr) |
| CL (2) | CL2015000255A1 (fr) |
| CY (1) | CY1122610T1 (fr) |
| DK (1) | DK2892891T3 (fr) |
| EA (1) | EA027244B1 (fr) |
| EC (1) | ECSP15012804A (fr) |
| ES (1) | ES2748798T3 (fr) |
| GE (1) | GEP20176631B (fr) |
| HR (1) | HRP20191755T1 (fr) |
| HU (1) | HUE046996T2 (fr) |
| IL (1) | IL236987A (fr) |
| LT (1) | LT2892891T (fr) |
| MA (1) | MA37891B1 (fr) |
| MD (1) | MD4425C1 (fr) |
| MX (1) | MX338887B (fr) |
| NZ (1) | NZ703989A (fr) |
| PE (1) | PE20151001A1 (fr) |
| PH (1) | PH12015500457B1 (fr) |
| PL (1) | PL2892891T3 (fr) |
| PT (1) | PT2892891T (fr) |
| RS (1) | RS59394B1 (fr) |
| SG (2) | SG11201500861QA (fr) |
| SI (1) | SI2892891T1 (fr) |
| TN (1) | TN2015000054A1 (fr) |
| TW (1) | TWI586661B (fr) |
| UA (1) | UA115881C2 (fr) |
| UY (1) | UY35012A (fr) |
| WO (1) | WO2014039434A1 (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ703989A (en) * | 2012-09-07 | 2017-04-28 | Boehringer Ingelheim Int | Alkoxy pyrazoles as soluble guanylate cyclase activators |
| TW201625584A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
| WO2016014463A1 (fr) | 2014-07-22 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Acides carboxyliques hétérocycliques en tant qu'activateurs de la guanylate cyclase soluble |
| WO2017103888A1 (fr) | 2015-12-18 | 2017-06-22 | Novartis Ag | Dérivés d'indane et leur utilisation comme activateurs de la guanylate cyclase soluble |
| WO2018069148A1 (fr) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Combinaison contenant des activateurs gcs et des antagonistes du récepteur des minéralocorticoïdes |
| WO2019081456A1 (fr) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | Utilisation d'activateurs et de stimulateurs de sgc comprenant une sous-unité bêta2 |
| EP3498298A1 (fr) | 2017-12-15 | 2019-06-19 | Bayer AG | Utilisation de stimulateurs sgc et d'activateurs sgc seuls ou en combinaison avec des inhibiteurs pde5 pour le traitement de troubles osseux, y compris l'ostéogénèse imparfaite (oi) |
| CN112055584A (zh) | 2018-04-30 | 2020-12-08 | 拜耳公司 | sGC活化剂和sGC刺激剂用于治疗认知障碍的用途 |
| JP2021523201A (ja) | 2018-05-15 | 2021-09-02 | バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 神経線維感作に関連する疾患を治療するための１，３−チアゾール−２−イル置換ベンズアミド |
| US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
| EA202190193A1 (ru) * | 2018-07-12 | 2021-06-16 | Бёрингер Ингельхайм Интернациональ Гмбх | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы |
| US20220128561A1 (en) | 2019-01-17 | 2022-04-28 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc) |
| EP3976591B1 (fr) * | 2019-10-18 | 2023-04-19 | FMC Corporation | Procédés de préparation d'acide 5-bromo-2-(3chloro-pyridin-2-yl)-2h-pyrazole-3-carboxylique |
| CN112079712B (zh) * | 2020-09-18 | 2022-12-13 | 江苏美迪克化学品有限公司 | 一种对乙烯基水杨酸的制备方法 |
| EP4011873A1 (fr) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Acides carboxyliques de pyrazolo pipéridine substitués |
| ES2997117T3 (en) * | 2020-12-10 | 2025-02-14 | Bayer Ag | Substituted pyrazolo piperidine carboxylic acids |
| GB202102895D0 (en) | 2021-03-01 | 2021-04-14 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| CN118900690A (zh) | 2022-03-21 | 2024-11-05 | 勃林格殷格翰国际有限公司 | 用于治疗门脉高压的可溶性鸟苷酸环化酶活化剂 |
| CA3258617A1 (fr) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Activateurs de guanylate cyclase soluble destinés à être utilisés dans le traitement de l'insuffisance cardiaque à fraction d'éjection préservée chez les femmes |
| WO2024097316A1 (fr) | 2022-11-04 | 2024-05-10 | Boehringer Ingelheim International Gmbh | Activateurs de guanylate cyclase soluble pour le traitement de la sclérose systémique |
| WO2024123847A1 (fr) | 2022-12-09 | 2024-06-13 | Boehringer Ingelheim International Gmbh | Formes solides d'un activateur de sgc |
| CN121620369A (zh) | 2023-08-16 | 2026-03-06 | 勃林格殷格翰国际有限公司 | 用于治疗临床显著门静脉高压和失代偿期肝硬化的可溶性鸟苷酸环化酶激活剂 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9824310D0 (en) * | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| AU2002214626A1 (en) | 2000-09-29 | 2002-04-08 | Cor Therapeutics, Inc. | Quaternary amines and related inhibitors of factor xa |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| AU2002228819A1 (en) | 2000-11-22 | 2002-06-03 | Visx Incorporated | Temperature actuated positioning device for non-linear optical elements |
| GB0212785D0 (en) | 2002-05-31 | 2002-07-10 | Glaxo Group Ltd | Compounds |
| AU2003297431A1 (en) | 2002-12-20 | 2004-07-22 | Pharmacia Corporation | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds |
| CA2615426A1 (fr) | 2005-07-18 | 2007-01-25 | Bayer Healthcare Ag | Nouvelle utilisation d'activateurs et de stimulateurs de la guanylate cyclase soluble permettant de prevenir ou de traiter des troubles renaux |
| US20080045560A1 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Pyrrolidine and related derivatives useful as PR modulators |
| AU2008250643A1 (en) * | 2007-05-12 | 2008-11-20 | Bayer Schering Pharma Aktiengesellschaft | sGC stimulators, sGC activators and combinations for the treatment of urological disorders |
| CA2698332C (fr) * | 2007-09-06 | 2012-08-21 | Merck Sharp & Dohme Corp. | Derives pyrazole en tant qu'activateurs de la guanylate-cyclase soluble |
| MX2010003071A (es) * | 2007-10-05 | 2010-04-01 | Sanofi Aventis Deutschland | Uso de n-fenilamidas de acido 2-sulfonilaminobenzoico sustituidas con sulfonilo en el tratamiento del dolor. |
| WO2009068652A1 (fr) | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | Pyridines 2, 6-disubstituées et pyrimidines 2, 4-disubstituées en tant qu'activateurs de guanylate cyclase soluble |
| PE20091258A1 (es) * | 2007-12-03 | 2009-09-12 | Smithkline Beecham Corp | Derivados de piridina como activadores de la guanilato ciclasa soluble |
| WO2009123316A1 (fr) | 2008-04-04 | 2009-10-08 | 武田薬品工業株式会社 | Dérivé hétérocyclique et son utilisation |
| WO2010015652A2 (fr) | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Composés thiazole utilisés comme activateurs de la guanylate cyclase soluble |
| WO2010015653A1 (fr) * | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Dérivés de pyrimidine comme activateurs de guanylate cyclase soluble |
| US8741910B2 (en) | 2008-11-25 | 2014-06-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| BRPI1006869A2 (pt) * | 2009-01-17 | 2016-03-15 | Bayer Schering Pharma Ag | estimuladores de sgc ou ativadores da sgc em combinação com inibidores da pde5 para o tratamento de disfunção erétil |
| CN102414194A (zh) | 2009-02-26 | 2012-04-11 | 默沙东公司 | 可溶性鸟苷酸环化酶激活剂 |
| WO2011095553A1 (fr) | 2010-02-05 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft | Stimulateurs de sgc ou activateurs de sgc en combinaison avec des inhibiteurs de pde5 pour le traitement du dysfonctionnement érectile |
| KR101793304B1 (ko) * | 2010-02-05 | 2017-11-02 | 아드베리오 파마 게엠베하 | 낭성 섬유증의 치료를 위한, 단독으로의 및 ＰＤＥ5 억제제와 조합된 ｓＧＣ 자극제 또는 ｓＧＣ 활성화제 |
| CN103038232B (zh) * | 2010-05-26 | 2016-01-20 | 阿德弗里奥药品有限责任公司 | 单独的和与PDE5抑制剂相组合的sGC刺激剂、sGC活化剂用于治疗系统性硬化症(SSc)的用途 |
| EP2585055A1 (fr) | 2010-06-25 | 2013-05-01 | Bayer Intellectual Property GmbH | Utilisation de stimulateurs et d'activateurs de la guanylate-cyclase soluble pour le traitement de la drépanocytose et la conservation de substituts sanguins |
| EP2632551B1 (fr) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Activateurs de la guanylate cyclase soluble |
| JP5715713B2 (ja) | 2011-03-10 | 2015-05-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性グアニル酸シクラーゼ活性化因子 |
| US8815857B2 (en) | 2011-08-12 | 2014-08-26 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
| EP2594270A3 (fr) | 2011-11-18 | 2013-07-31 | BIP Patents | Utilisation de stimulateurs de la sGC ou d'activateurs de la sGC, seuls et en combinaison avec des inhibiteurs de PDE5 pour le traitement de la sclérose systémique (Ssc) |
| NZ703989A (en) * | 2012-09-07 | 2017-04-28 | Boehringer Ingelheim Int | Alkoxy pyrazoles as soluble guanylate cyclase activators |
-
2013
- 2013-09-03 NZ NZ703989A patent/NZ703989A/en unknown
- 2013-09-03 GE GEAP201313783A patent/GEP20176631B/en unknown
- 2013-09-03 SG SG11201500861QA patent/SG11201500861QA/en unknown
- 2013-09-03 PE PE2015000295A patent/PE20151001A1/es active IP Right Grant
- 2013-09-03 MD MDA20150019A patent/MD4425C1/ro active IP Right Grant
- 2013-09-03 SG SG10201510668UA patent/SG10201510668UA/en unknown
- 2013-09-03 HR HRP20191755TT patent/HRP20191755T1/hr unknown
- 2013-09-03 SI SI201331583T patent/SI2892891T1/sl unknown
- 2013-09-03 BR BR112015004529-4A patent/BR112015004529B1/pt active IP Right Grant
- 2013-09-03 US US14/016,452 patent/US8906904B2/en not_active Ceased
- 2013-09-03 WO PCT/US2013/057826 patent/WO2014039434A1/fr not_active Ceased
- 2013-09-03 ES ES13762666T patent/ES2748798T3/es active Active
- 2013-09-03 UA UAA201503030A patent/UA115881C2/uk unknown
- 2013-09-03 PT PT137626669T patent/PT2892891T/pt unknown
- 2013-09-03 CN CN201380046266.3A patent/CN104619695B/zh active Active
- 2013-09-03 RS RSP20191306 patent/RS59394B1/sr unknown
- 2013-09-03 CA CA2880494A patent/CA2880494C/fr active Active
- 2013-09-03 JP JP2015531142A patent/JP5970134B2/ja active Active
- 2013-09-03 DK DK13762666.9T patent/DK2892891T3/da active
- 2013-09-03 MX MX2015002807A patent/MX338887B/es active IP Right Grant
- 2013-09-03 PL PL13762666T patent/PL2892891T3/pl unknown
- 2013-09-03 AU AU2013312931A patent/AU2013312931B2/en active Active
- 2013-09-03 LT LTEP13762666.9T patent/LT2892891T/lt unknown
- 2013-09-03 AP AP2015008231A patent/AP2015008231A0/xx unknown
- 2013-09-03 EA EA201500298A patent/EA027244B1/ru not_active IP Right Cessation
- 2013-09-03 KR KR1020157005961A patent/KR101692707B1/ko active Active
- 2013-09-03 MA MA37891A patent/MA37891B1/fr unknown
- 2013-09-03 HU HUE13762666A patent/HUE046996T2/hu unknown
- 2013-09-03 EP EP13762666.9A patent/EP2892891B1/fr active Active
- 2013-09-06 AR ARP130103197A patent/AR092869A1/es active IP Right Grant
- 2013-09-06 UY UY0001035012A patent/UY35012A/es active IP Right Grant
- 2013-09-06 TW TW102132286A patent/TWI586661B/zh active
-
2015
- 2015-01-29 IL IL236987A patent/IL236987A/en active IP Right Grant
- 2015-02-03 CL CL2015000255A patent/CL2015000255A1/es unknown
- 2015-02-18 TN TNP2015000054A patent/TN2015000054A1/fr unknown
- 2015-03-03 PH PH12015500457A patent/PH12015500457B1/en unknown
- 2015-03-06 CL CL2015000562A patent/CL2015000562A1/es unknown
- 2015-04-02 EC ECIEPI201512804A patent/ECSP15012804A/es unknown
-
2016
- 2016-10-31 US US15/338,605 patent/USRE46886E1/en active Active
-
2019
- 2019-10-22 CY CY20191101099T patent/CY1122610T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA37891A1 (fr) | Alcoxypyrazoles comme activateurs de guanylate cyclase soluble | |
| WO2019035863A8 (fr) | Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques | |
| MA34819B1 (fr) | Dérivés bicyclo[3.2.1]octylamide et leurs utilisations | |
| MA37400B1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| MA35109B1 (fr) | Derives de nucleoside 2-substitues et procedes d'utilisation de ceux-ci pour le traitement de maladies virales | |
| MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
| MA31142B1 (fr) | Derives heteroaryles de pyrrolidinyl et piperdinyl cetones. | |
| MA32471B1 (fr) | Composés de borates esters et compositions pharmaceutiques contenant des composés | |
| TN2014000115A1 (fr) | Derives de pyrrolopyrimidines et de purines | |
| MA37762A1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
| MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
| MA38138A1 (fr) | Dérivés inédits de quinolone | |
| MA34896B1 (fr) | Inhibiteurs du virus de l'hepatite c | |
| MA30207B1 (fr) | Modulateurs des recepteurs de la progesterone a base d'indole sulfonamide | |
| EA201001733A1 (ru) | Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк) | |
| MA37886B1 (fr) | Nouvelles pyridinones bicycliques | |
| MA33420B1 (fr) | Dérivés fluorés de l'aminotriazole | |
| MA39165A1 (fr) | Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires | |
| MA38315B1 (fr) | Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales | |
| MA37831B1 (fr) | Dérivés d'azaindole agissant comme inhibiteur de pi3k | |
| MA35893B1 (fr) | Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7 | |
| MA30821B1 (fr) | Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes | |
| CA2878796C (fr) | Derives de pyridinone comme inhibiteurs de la transglutaminase tissulaire | |
| MA35104B1 (fr) | Inhibiteur du virus de l'hepatite c | |
| MA39043A1 (fr) | Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs |